Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC. Blum KA, et al. Among authors: chan kk. Br J Haematol. 2010 Jul;150(2):189-95. doi: 10.1111/j.1365-2141.2010.08213.x. Epub 2010 Apr 29. Br J Haematol. 2010. PMID: 20456354 Free PMC article. Clinical Trial.
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. Blum W, et al. Among authors: chan kk. J Clin Oncol. 2007 Sep 1;25(25):3884-91. doi: 10.1200/JCO.2006.09.4169. Epub 2007 Aug 6. J Clin Oncol. 2007. PMID: 17679729 Clinical Trial.
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Blum W, et al. Among authors: chan kk. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. doi: 10.1073/pnas.1002650107. Epub 2010 Apr 5. Proc Natl Acad Sci U S A. 2010. PMID: 20368434 Free PMC article. Clinical Trial.
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci G. Klisovic RB, et al. Among authors: chan kk. Leuk Lymphoma. 2014 Jun;55(6):1332-6. doi: 10.3109/10428194.2013.838764. Epub 2013 Nov 1. Leuk Lymphoma. 2014. PMID: 24015841 Free PMC article. Clinical Trial.
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. Klisovic RB, et al. Clin Cancer Res. 2008 Jun 15;14(12):3889-95. doi: 10.1158/1078-0432.CCR-08-0109. Clin Cancer Res. 2008. PMID: 18559610 Free PMC article. Clinical Trial.
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Marcucci G, et al. Among authors: chan kk. J Clin Oncol. 2005 May 20;23(15):3404-11. doi: 10.1200/JCO.2005.09.118. Epub 2005 Apr 11. J Clin Oncol. 2005. PMID: 15824414 Clinical Trial.
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G. Liu S, et al. Among authors: chan kk. Blood. 2008 Feb 15;111(4):2364-73. doi: 10.1182/blood-2007-08-110171. Epub 2007 Dec 14. Blood. 2008. PMID: 18083845 Free PMC article.
Curcumin is a potent DNA hypomethylation agent.
Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, Li C, Chan KK. Liu Z, et al. Among authors: chan kk. Bioorg Med Chem Lett. 2009 Feb 1;19(3):706-9. doi: 10.1016/j.bmcl.2008.12.041. Epub 2008 Dec 14. Bioorg Med Chem Lett. 2009. PMID: 19112019
1,177 results